TARGET-HBV observational study begins enrollment

TARGET PharmaSolutions initiated patient enrollment for an observational study of patients with chronic hepatitis B to gather real-world data and advance the understanding of HBV, according to a press release.

“TARGET-HBV is timely given the renewed interest in finding a cure for hepatitis B,” Anna S. Lok, MD, FAASLD, from the University of Michigan and TARGET-HBV scientific advisor, said in the release. “Chronic hepatitis B is characterized by fluctuations in virus replication and disease activity; thus, while guidelines exist, management of individual patients can be nuanced. Data on a large cohort of hepatitis B patients managed in the real-world will provide insights into the course of this disease and guide the use of future therapies.”

The company plans to enroll up to 5,000 patients in the “TARGET-HBV” study from a large network of academic and community sites across the U.S.

“We are very excited that we have started enrolling patients in our TARGET-HBV community,” Meg Powell, PharmD, CEO of TARGET PharmaSolutions, said in the release. “We have seen significant interest from investigative sites to participate in this important study, and we look forward to continuing to advance the understanding of this challenging disease.”

Reference: www.targetpharmasolutions.com